Hemoperfusion in patients with COVID-19

Phase 2

• Conditions: Condition 1: COVID-19. Condition 2: COVID-19.; U07.1: COVID-19, virus identified; U07.2: COVID-19, virus not identified; U07.1; U07.2

• Registration Number: IRCT20150704023055N2
• Lead Sponsor: Babol University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 April 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

Patients with diagnosis of COVID-19 based on the clinical manifestations, lung CT-scan, testing of pharyngeal sample using real-time polymerase chain reaction and the physician´s diagnosis
Patients who have partial pressure of oxygen in alveoli (PaO2) less than 60, even after different methods of oxygen-therapy
Patients who have partial pressure of oxygen in alveoli to the fraction of inspired oxygen (PaO2/FiO2) less than 200
Patients who have partial pressure of carbon dioxide in alveoli (PaCo2) more than 50; PH less than 7.35; peripheral capillary oxygen saturation (SpO2) less than 88%; and no improvement has been achieved despite 48 hours of non-invasive respiratory therapy

Exclusion Criteria

Plasma platelet count less than 30000 per microliter
Multiple organ dysfunction

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improving the general condition of the patient. Timepoint: Before intervention and one week after the third session of hemoperfusion. Method of measurement: No need to receive any intensive respiratory care in the patient.

Secondary Outcome Measures

Name	Time	Method
Serum level of interleukin- 6. Timepoint: Before the first and after the third session of hemoperfusion. Method of measurement: To test the blood sample.